The era of Mad Seedling without serum has arrived! Emmy (06660) Serum-free Iterative Mad has completed the submission of supplementary materials for listing registration

Zhitong Finance App News, Le Meridien Vaccine (06660) announced on August 3 that the company has independently developed a serum-free iterative rabies vaccine. It has previously submitted a marketing registration application to the State Drug Administration, and has successfully completed on-site verification. In the first half of this year, Le Meridien Honors received the CDE supplementary information notice. As a routine process during the vaccine review stage, the company has completed the data in accordance with the review opinions and submitted supplementary data to the CDE, and significant progress has been made in the registration and application process for the serum-free iterative rabies vaccine.

Earlier, industry insiders commented that serum-free technology is undoubtedly a valuable exploration direction in the field of vaccine production processes, representing the industry's efforts to pursue higher standards and continuously innovate itself. Its emergence has provided new possibilities for future vaccine production. As the second largest producer of wild seedlings in the world, Le Méridien has gradually turned this exploration of innovative technology into reality.

According to the results of a phase III clinical study that has completed decontamination, the serum-free iterative rabies vaccine developed by Le Méridien has good safety, immunogenicity, and immune persistence, and has fully met the pre-defined evaluation criteria for clinical trials. Le Meridien has previously obtained a product production license corresponding to the serum-free iterative rabies vaccine. With the launch of the serum-free rabies vaccine, Le Méridien will further strengthen its position as a global leader in rabies vaccines.

Earlier, at an industry forum, some experts pointed out that since the rabies vaccine was introduced, it has been gradually iterated and upgraded from generation to generation. Serum-free Mad Vaccine is the latest generation product. It is recommended that the market pay more attention and learn more about this new product. In addition, other experts pointed out that foreign studies have shown that the incidence of adverse reactions at the vaccination site of the serum-free rabies vaccine is significantly lower than that of the Vero cell rabies vaccine. However, the serum-free rabies vaccine that will soon be marketed by the Le Méridien vaccine has basically removed all high-risk components from the vaccine, which can be called the optimal solution for “cell culture rabies vaccine.” According to research and consultation statistics, driven by product updates and increased popularity of rabies vaccines, China's rabies vaccine market is expected to reach 14.8 billion yuan in 2030. Aimee's serum-free iterative vaccine has been approved for marketing and sales, which is expected to bring about a significant increase in performance.